Abstract library

357 results for "pancreas".
#591 Pancreastatin: A Predictive Neuroendocrine Tumor Marker
Introduction: Pancreastatin is a derived peptide of CgA. Pancreastatin has the potential to be a diagnostic and predictive tumor marker in detecting NETs.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Sapna Rustagi
Keywords: pancreastatin, NETs, CgA
#110 Slug represents an important regulator of E-cadherin expression in neuroendocrine tumor cells of the pancreas
Introduction: Neuroendocrine tumors of the pancreas form an inhomogenous group of epithelial neoplasms. They differ from other types of pancreatic cancers by showing an extended survival of patients, which is due to a mostly slow proliferation rate of the tumor. However, some of these neuroendocrine tumors are characterized by an early onset of metastases, which cannot be predicted by any available method. The epithelial to mesenchymal transition (EMT) represents a central part of cell migration and metastasis. During EMT, cells loosen their cellular contacts, leave the tissue, and become migrating single cells. One of the integral compounds of cell adhesion represents the E-cadherin adhesion module, which contains mostly E-cadherin and several catenins. A loss of this adhesion module is associated with tumor progression, migration and metastasis in many types of cancer.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Alexander König
#1283 Heterotopic Pancreas Mimicking a Gastrointestinal Neuroendocrine Tumor: A Case Report
Introduction: Heterotopic pancreas, defined as an atypical presence of pancreatic tissue with no anatomic or vascular continuity with the pancreas, is relatively rare. In most cases it is diagnosed during autopsy or incidentally, since it becomes symptomatic only in few cases, causing bleeding, pain or obstruction.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: dr Sara Massironi
#1689 The Prognostic Value of the Expression of Cytokeratin 7 and 19 in Lungs and Pancreas Neuroendocrine Tumors
Introduction: The expression of cytokeratins (CK) 7,19 rarely occurs in the low grade neuroendocrine tumors (NET) of lung and pancreas. It is known that part of the low grade typical (TC) and atypical (ATС) carcinoids of lung and pancreas (pNET-G1,G2) can progress quickly and to metastasize. It is important to distinguish NET with a less differentiated cells immunophentype.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Iya A Voronkova
#386 A Prospective Evaluation of the Effects of Chronic Proton Pump Inhibitor Use on Plasma Biomarker Levels in Humans
Introduction: Proton pump inhibitors (PPIs) are used primarily to treat gastroesophageal reflux disease. PPI-induced achlorhydria increases circulating gastrin and chromogranin A (CGA). CGA is a widely used biomarker for the diagnosis and follow-up for gut-based neuroendocrine tumors (NETs). PPI-induced increases in CGA or gastrin may falsely suggest the presence of a NET when none exists. Pancreastatin, a fragment of CGA, is also commonly used to diagnose and follow NETs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Eugene Woltering
#515 Neuroendocrine Carcinomas (NEC) of the Pancreas: A Land of Hope?
Introduction: Poorly differentiated neuroendocrine carcinomas (NEC) of the pancreas are historically associated with poor prognosis. Contemporary data regarding their treatment and survival are scant.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Letizia Boninsegna
#531 Long-Term Outcomes in 50 Consecutive Patients with Neuroendocrine Tumors of the Pancreas
Introduction: Recently, the new World Health Organization (WHO) classification and TNM staging for neuroendocrine tumors of the pancreas (pNETs) were published.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Takeshi Natori
Authors: Natori T, Katori M, Seki M, ...
#827 Neuroendocrine Tumors of the Pancreas Grade 2 with Ki-67 Index More Than 5% and with Expression Cytokeratin 19 are the Risk Group of Rapid Progression
Introduction: Cytokeratin 19 (CK19) is the marker of pluripotent cells of the epithelium of the pancreatic ducts, which is not detected in differentiated endocrine cells. Our experience shows that many patients with neuroendocrine tumors of the pancreas (pNET) G2 have a rapid progression of the disease a few years after diagnosis, and metastases are found most commonly in the liver.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: MD Larisa Gurevich
#1930 Concomitant Intraductal Papillary Mucinous Neoplasms and Neuroendocrine Tumors of the Pancreas: More than just a Coincidence?
Introduction: Intraductal papillary mucinous neoplasms (IPMNs) and pancreatic neuroendocrine tumors (pNETs) are rare tumors. Up to now 14 patients with association of
endocrine and exocrine neoplasms of the pancreas have been reported in literature: this association is not expected to be frequent
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Pablo Cortegoso Valdivia
Keywords: IPMN, NET, pancreas
#439 Chromogranin A (CgA) and Pancreastatin (PcSt) as Predictors of Peptide Receptor Radionuclide Therapy (PRRT) Outcomes in Patients with Metastatic Well-Differentiated Neuroendocrine Tumors (mNETs)
Introduction: CgA and PcSt are widely used in assessing response to treatment in mNETs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Nancy Sharma